Chicago / Edinburgh
LATEST FROM IPOX®

News

News and updates from IPOX®, including media mentions, interviews, research and press releases.

Reuters: IPOX® Associate Lukas Muehlbauer Comments on Doncasters’ U.S. IPO and NYSE debut.

Reuters: IPOX® Associate Lukas Muehlbauer Comments on Doncasters’ U.S. IPO and NYSE debut.

Reuters featured IPOX® Associate Lukas Muehlbauer in two articles covering Doncasters’ U.S. IPO and NYSE debut. The aerospace parts maker raised $919.3 million after pricing above its marketed range, then opened 33.3% higher in its first trading session. Muehlbauer discussed Doncasters’ nearly 250-year heritage, post-2020 turnaround, revenue growth, and broader positioning across aerospace, defense, industrial gas turbines, and AI-linked power demand, noting that its investment story extends beyond a pure-play defense theme for Reuters readers following IPO markets closely.

Reuters: IPOX® CEO Josef Schuster Comments on Safepoint’s Withdrawn U.S. Listing Plans

Reuters: IPOX® CEO Josef Schuster Comments on Safepoint’s Withdrawn U.S. Listing Plans

IPOX® CEO Josef Schuster commented on Safepoint’s decision to withdraw its planned U.S. listing, telling Reuters that the move appeared to reflect company-specific factors rather than weakness in the broader IPO market. The Florida insurer had sought to raise up to $283.3 million after launching its IPO in May. Reuters noted that the withdrawal came as the IPO market continued to regain momentum, with several Florida-based insurers already completing New York listings in 2025, following recent reforms in Florida’s market.

First Trust ROI Podcast: IPOX® Dr. Josef Schuster Discusses Post-IPO Performance Trends and New Listings Market

First Trust ROI Podcast: IPOX® Dr. Josef Schuster Discusses Post-IPO Performance Trends and New Listings Market

IPOX® CEO Josef Schuster featured on the First Trust ROI Podcast to discuss post-IPO performance trends, renewed activity in the IPO market, and key dynamics shaping new listings. Schuster highlighted IPOX® research on the long-term divergence between IPO winners and underperformers, the role of diversification in post-IPO investing, and opportunities across IPOs, spin-offs, SPACs, and international markets as investor interest in newly public companies continues to strengthen.

Reuters: IPOX® Associate Muehlbauer Comments on Lime’s U.S. IPO Valuation and Market Risks

Reuters: IPOX® Associate Muehlbauer Comments on Lime’s U.S. IPO Valuation and Market Risks

IPOX® Associate Muehlbauer commented on Lime’s planned U.S. IPO in Reuters, highlighting the Uber-backed electric bike and scooter operator’s global scale, cash generation, and strong revenue growth as supportive factors for its proposed valuation of up to $1.66 billion. His analysis also noted key market considerations, including seasonality, regulation, asset intensity, and city-level permit exposure, as Lime prepares to list on Nasdaq under the ticker LIME.

Reuters: IPOX® Associate Lukas Muehlbauer Comments on Kardigan’s Nasdaq Debut and Biotech IPO Market Trends

Reuters: IPOX® Associate Lukas Muehlbauer Comments on Kardigan’s Nasdaq Debut and Biotech IPO Market Trends

IPOX® Associate Muehlbauer was quoted by Reuters on Kardigan’s Nasdaq debut, after the heart drug developer raised $400 million in an upsized IPO. He noted that biotech IPO activity has improved but remains selective, favoring companies with late-stage assets, clear commercialization paths, visible catalysts, or strong backers. In broader commentary shared with Reuters, Muehlbauer said Kardigan’s going-concern warning was not a deal breaker and reflected why the company raised capital, while follow-on offerings remain a possible overhang for investors.

Reuters: IPOX® Analyst Kat Liu Comments on SpaceX’s Post-IPO Share Decline

Reuters: IPOX® Analyst Kat Liu Comments on SpaceX’s Post-IPO Share Decline

IPOX® VP Kat Liu was quoted by Reuters on SpaceX’s post-IPO share decline, as the stock fell more than 6% after a sharp debut rally. Reuters reported that shares remained over 30% above the $135 offering price, while investors weighed valuation, limited float, retail activity and AI expansion plans. Liu noted that profit-taking was not surprising given the IPO’s scale and strong initial performance, calling it an eventful, shortened trading week for the largest IPO in history.

Reuters: IPOX® Research Associate Lukas Muehlbauer Comments on SPAC Revival Amid Mega-IPO Frenzy

Reuters: IPOX® Research Associate Lukas Muehlbauer Comments on SPAC Revival Amid Mega-IPO Frenzy

IPOX® Associate Muehlbauer noted in Reuters coverage that some companies previously considering a traditional IPO may now look to SPAC mergers as mega-IPOs compete for investor attention. He said existing SPAC vehicles still need to complete transactions before liquidation, leaving capital actively seeking deals. Reuters highlighted renewed SPAC activity and rising issuance, while IPOX® data show the IPOX® SPAC Index outperforming the S&P 500 year to date, up 16.43% versus 9.73% amid a more favorable public-market backdrop for new listings.

First Trust Webinar: IPOX® CEO Josef Schuster Discusses SpaceX IPO, New Listings, and IPOX® Index Methodology

First Trust Webinar: IPOX® CEO Josef Schuster Discusses SpaceX IPO, New Listings, and IPOX® Index Methodology

In a First Trust webinar, IPOX® CEO Dr. Josef Schuster discussed the SpaceX IPO, strong new-listings activity, and IPOX®’s data-driven approach to tracking IPOs, spin-offs, de-SPACs, REITs, and select IPO M&A. Schuster addressed SpaceX’s expected low float, aftermarket risks, and broader opportunities across the IPO market. The webinar also highlighted the IPOX® 100 U.S. Index, its 20-year live track record, and its role as the underlying index for the First Trust US Equity Opportunity Index (Ticker FPX) today.

Reuters: IPOX® Associate Lukas Muehlbauer Comments on Doncasters’ U.S. IPO and Aerospace Listing Momentum

Reuters: IPOX® Associate Lukas Muehlbauer Comments on Doncasters’ U.S. IPO and Aerospace Listing Momentum

IPOX® Associate Muehlbauer commented in Reuters on Doncasters’ planned U.S. IPO, as the aerospace parts maker targets a valuation of up to $4.43 billion and seeks to raise as much as $746.7 million. Muehlbauer noted that aerospace and defense sector momentum could support strong pricing, especially for companies showing demand through government contracts, long-term agreements and backlogs. He also cautioned that investors will focus on whether Doncasters’ capacity investments can translate into profits as it remains loss-making during expansion.

THE IPOX® NEWSLETTERS

Stay ahead of the next listing.

Research and insight from the global new listings market.

Explore our newsletters